Smartphone-based COVID-19 test garners U.S. FDA emergency use authorization

Feb. 16, 2021
Luminostics’ Clip COVID Rapid Antigen Test uses a smartphone-based analyzer to obtain results in 30 minutes from nasal swabs in decentralized settings.

Diagnostics company Luminostics (Milpitas, CA) has received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) and will scale up production activities for its Clip COVID rapid antigen test to meet testing demand in the fight against COVID-19. The test is a lateral flow immunoluminescent assay that uses glow-in-the-dark nanochemistry along with a smartphone’s optics, an inexpensive adapter, and artificial intelligence (AI) to detect SARS-CoV-2 viral antigens from nasal swabs in around 30 minutes.

The Clip COVID rapid antigen test is said to offer 100% specificity (negative percent agreement) and 96.9% sensitivity (positive percent agreement) compared to FDA-authorized, laboratory-based high-sensitivity real-time polymerase chain reaction (RT-PCR) in an independently run multisite prospective clinical study. Test results are objectively displayed on the smartphone’s screen, eliminating the sorts of errors that plague result interpretation of visual lateral flow tests. This objectivity, along with its minimal hands-on time, enables high-throughput processing of over 30 tests per operator per hour from sample collection to result. Automated result integration to electronic health record and laboratory information management systems, as well as automated result reporting to federal, state, and local public health authorities can easily be enabled by the Clip COVID mobile app to minimize the administrative burden of organizations that run rapid COVID tests.

Luminostics continues to increase its production capacity and expects to be manufacturing over 2 million tests per month by April 2021 and more than 4 million tests per month by the summer. Another immediate goal for the company is to expand Clip COVID’s EUA labeling to include non-prescription, non-laboratory use, according to Bala Raja, Ph.D., Luminostics co-founder and CEO.

Source: Luminostics press release via GlobeNewswire – February 15, 2021

About the Author

LFW Staff

Published since 1965, Laser Focus World—a brand and monthly magazine for engineers, researchers, scientists, and technical professionals—provides comprehensive global coverage of optoelectronic technologies, applications, and markets. With 80,000+ qualified print subscribers in print and over a half-million annual visitors to our online content, we are the go-to source to access decision makers and stay in-the-know.

Sponsored Recommendations

High-index glass cutting for AR enabled by ultrashort-pulsed lasers

Dec. 11, 2023
A laser-based separation process for cutting augmented reality (AR) eyepieces made of high-index glass achieves high and predictable bending strength, and has been integrated ...

Ask the Expert: Building Better Laser Micromachining Systems

Dec. 8, 2023
Dr. Cliff Jolliffe, Head of Strategic Marketing, Industrial Automation, Physik Instrumente (PI), fields questions about integrating controls for different motion systems and lasers...

Video: December 8, 2023 Photonics Hot List

Dec. 8, 2023
In this episode, we cover a microscopy method that hits uncharted cell territory, drone-based imaging for solar farm inspection, soliton microcombs that boost conversion efficiency...

China’s industrial laser market shows steady growth in turbulent times

Dec. 8, 2023
This in-depth market update focuses on trends in laser processing and industrial lasers while touching on what to expect in the ultrafast laser, fiber laser, LiDAR, and handheld...

Voice your opinion!

To join the conversation, and become an exclusive member of Laser Focus World, create an account today!